LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Cerrado

SectorSanidad

638.17 -0.53

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

633.36

Máximo

642.52

Métricas clave
By Trading Economics
Ingresos	-117M 727M
Ventas	-279M 3.6B
P/B Media del Sector	15.384 49.701
BPA	9.47
Rentabilidad por dividendo	0.51
Margen de beneficios	20.17
Empleados	15,343
EBITDA	-234M 967M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+29.13% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	0.51% 2.39%
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-12B 66B
Apertura anterior	638.7
Cierre anterior	638.17

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

542.44 / 599.76 Soporte y Resistencia

Regeneron Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 ago 2025, 11:33 UTC

Ganancias

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 abr 2026, 12:01 UTC

Ganancias

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 abr 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 mar 2026, 11:02 UTC

Charlas de Mercado

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 dic 2025, 08:30 UTC

Adquisiciones, fusiones, absorciones

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 ago 2025, 13:16 UTC

Ganancias

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 12:40 UTC

Ganancias

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 10:41 UTC

Ganancias

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 ago 2025, 10:41 UTC

Ganancias

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 ago 2025, 10:40 UTC

Ganancias

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 ago 2025, 10:38 UTC

Ganancias

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 ago 2025, 10:37 UTC

Ganancias

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 ago 2025, 10:35 UTC

Ganancias

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 ago 2025, 10:34 UTC

Ganancias

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 ago 2025, 10:33 UTC

Ganancias

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 ago 2025, 10:32 UTC

Ganancias

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 ago 2025, 10:31 UTC

Ganancias

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 ago 2025, 10:31 UTC

Ganancias

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 ago 2025, 10:30 UTC

Ganancias

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 ago 2025, 10:30 UTC

Ganancias

Regeneron Pharma 2Q Rev $3.68B >REGN

1 ago 2025, 10:30 UTC

Ganancias

Regeneron Pharma 2Q EPS $12.81 >REGN

1 ago 2025, 10:30 UTC

Ganancias

Regeneron Pharma 2Q Net $1.39B >REGN

13 jun 2025, 21:42 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 jun 2025, 20:45 UTC

Adquisiciones, fusiones, absorciones

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 jun 2025, 20:34 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 jun 2025, 01:41 UTC

Adquisiciones, fusiones, absorciones

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 may 2025, 08:58 UTC

Acciones populares

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Comparación entre iguales

Cambio de precio

Regeneron Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

29.13% repunte

Estimación a 12 Meses

Media 829.77 USD 29.13%

Máximo 995 USD

Mínimo 641 USD

De acuerdo con 22 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

22 ratings

Comprar

Mantener

Vender

De acuerdo con 22 analistas que ofrecen calificaciones bursátiles a para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

542.44 / 599.76Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.